EP
VTGN icon

EPIQ Partners’s VistaGen Therapeutics VTGN Stock Holding History

EPIQ Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-43,378
Closed -$1.15M – 84
2022
Q2 		$1.15M Buy
43,378
+4,666
+12% +$165K 0.7% 44
2022
Q1 		$1.44M Buy
38,712
+5,300
+16% +$231K 0.77% 45
2021
Q4 		$1.96M Buy
33,412
+2,875
+9% +$187K 1.04% 36
2021
Q3 		$2.51M Sell
30,537
-562
-2% -$48.8K 1.16% 33
2021
Q2 		$2.94M Buy
31,099
+1,700
+6% +$126K 1.47% 28
2021
Q1 		$1.88M Buy
+29,399
New +$1.96M 1.08% 36

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EPIQ Partners's VTGN Position: Q3 2022 in Review

EPIQ Partners sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 43,378 shares — an estimated $1.15M sold.

EPIQ Partners first reported a position in VTGN in Q1 2021 and held it in 6 quarters. The position peaked at $2.94M in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • EPIQ Partners reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • EPIQ Partners sold 43,378 VistaGen Therapeutics shares in Q3 2022, an estimated $1.15M.
  • EPIQ Partners first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 6 quarters.
  • EPIQ Partners's VistaGen Therapeutics position peaked at $2.94M in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on EPIQ Partners's 13F filing for Q3 2022, filed 14 Oct 2022.